A growth rate of 5.3 % is predicted for extracorporeal membrane oxygenation systems over the forecast period (2018 - 2026).

Over the forecast period (2018-2026), extracorporeal membrane oxygenation systems will grow at a 5.3% CAGR.

In patients suffering from severe respiratory failure, an extracorporeal membrane oxygenation system provides cardiac and respiratory support. The ECMO circuit includes cannulas, a pump, a blender and an oxygenator, which oxygenates the blood and removes carbon dioxide through an extracorporeal gas exchange device known as a membrane oxygenator. The modality of the ECMO system depends on the location of the drainage and reinfusion ports. As long as both drainage and reinfusion come from central veins, it is called venovenous ECMO, and if it comes from vein to artery, it is called venoarterial ECMO. A few possible indications for ECMO include severe acute respiratory distress syndrome (ARDS), acute hypercapnic respiratory failure, primary graft dysfunction post-lung transplantation, and pulmonary hypertension with right ventricular failure.


The prevalence of diseases will increase the demand for extracorporeal membrane oxygenation systems in hospitals and surgical centers. The Extracorporeal Life Support Organization (ELSO) reports that 65,171 patients received ECMO systems in 2015, a number that increased to 98,840 in 2018 among which 40,256 were neonates, 22,952 youngsters, and 35,632 adults.


Markets for extracorporeal oxygenation systems are segmented based on regions, including North America, Latin America, Europe, Africa, Asia Pacific, and the Middle East. Due to several factors, including a well-established healthcare infrastructure and government funding, North America dominates the ECMO system market. This region is expected to grow fast due to the high number of chronic lung diseases, such as Chronic Obstructive Pulmonary Disease (COPD). Furthermore, approximately 85 million and 49 million people in Europe and the European Union, respectively, suffered from cardiovascular disease in 2015. In 2011, the Centers for Disease Control, Prevention, and Treatment (CDC) reported that COPD was the third leading cause of death with over 15 million Americans suffering from COPD every year. A major factor driving Asia Pacific's share of the ECMO market is the evolution of the health care system alongside government initiatives.
vv

Post a Comment

Previous Post Next Post